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Obstructive sleep apnea(OSA) is one of the most common sleep disorders in kidney transplant recipients,
however its long-term consequences have only rarely been investigated. Here, we hypothesized that the
presence of OSA would be associated with higher risk of mortality and faster decline of graft function in
kidney transplant recipients. In a prospective cohort study 100 prevalent kidney transplant recipients who
underwent one-night polysomnography at baseline and were followed for amedian 75months. Generalized
linearmixed-effectsmodels andCox regressionmodels were used to assess the association betweenOSA and
the rate of progression of chronic kidney disease(CKD) and mortality. The estimated slopes of estimated
glomerular filtration rate(eGFR) in patients with and without OSAwere compared using a two-stagemodel
of eGFR change including only OSA as a variable. In this model patients with OSA (eGFR versus time was
20.93 ml/min/1.73 m2/yr(95%CI:21.75 to20.11) had a similar slope as compared to patients without
OSA(eGFR versus time was 21.24 ml/min/1.73 m2/yr(95%CI: 21.67 to 20.81). In unadjusted Cox
proportional regression analyses OSA was not associated with higher all-cause mortality risk (Hazard
Ratio(HR)5 1.20; 95%Confidence Interval(CI): 0.50–2.85). No associationwas found between the presence
of OSA and the rate of progression of CKD or all-cause mortality in prevalent kidney transplant recipients.
O
bstructive sleep apnea (OSA) is one of the most clinically important forms of sleep-related breathing
disorders. The prevalence of moderate and severe obstructive OSA (AHI $ 15 and the presence of
daytime symptoms of OSA) is 2–4% in the general population1. OSA is associated with increased
cardiovascular morbidity and mortality2,3. OSA is reportedly associated with higher risk of stroke, hypertension,
diabetesmellitus, congestive hearth failure, arrhythmias and themetabolic syndrome and also with fatal and non-
fatal cardiovascular (CV) events4–7.
Previous studies have shown high prevalence of OSA (16–54%) in patients with chronic kidney disease
(CKD)8,9, indicating that OSA is more common in hemodialyzed patients than in general population10. Earlier
we reported a similarly high prevalence of OSA in kidney transplant recipients compared to waitlisted dialysis
patients11. However, Mallamaci et al. found that OSAwas not more common in kidney transplant recipients than
age, body mass index (BMI) and gender matched individuals from general population12.
Despite the potential clinical relevance, the long-term consequences of OSA have only rarely been investigated
among kidney transplant recipients. The association between OSA and hypertension, accelerated atherosclerosis
and vascular damage was confirmed in patients with CKD13. The complex pathophysiology that links OSA to CV
risk may also have a detrimental effect on renal function. Indeed, Kinebuchy et al. documented glomerular
hyperfiltration in patients with OSA, which was alleviated by short-term continuous positive airway pressure
(CPAP) treatment suggesting that OSA may be a risk factor of progressive renal dysfunction14.
We designed this prospective cohort study to determine the association between presence of OSA and long-
term outcome, such as the decline of graft function and all-cause mortality in a randomly selected sample of
stable, prevalent kidney transplant recipients. OSAwas assessed using polysomnography at baseline. Based on the
previous findings we hypothesized that the presence of OSA would be associated with faster decline of graft
function and higher risk of mortality.
Results
Demographic data and baseline characteristics of the sample. The SLeep disorders Evaluation in Patients after
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estimated glomerular filtration rate (eGFR), blood hemoglobin,
serum albumin) of the 100 participating transplant (Tx) patients
(‘‘Tx study sample’’) were similar to the characteristics of the ‘‘total
clinic population’’ (Figure S1). Baseline patient characteristics are
shown in Table 1. Eighty-five percent of the patients were taking
steroids, 43% were administered cyclosporine A microemulsion
formulation (CsA), 71% were on mycophenolate-mofetil (MMF),
46% patients were administered tacrolimus and 5% were on
azathioprine. Only 1% and 12% of the patients took everolimus
and sirolimus, respectively. Six percent of our patients had at least
one previous transplantation.
The percentage of male patients was significantly higher among
patients with versus without apnea-hypopnea index (AHI) $ 15/h.
The prevalence of mild (5/h # apnea-hypopnea index (AHI) , 15/
h), moderate (15/h # AHI , 30/h) and severe OSA (AHI $ 30/h)
was 18%, 11% and 14% in our kidney transplant recipients11. We did
not find any association between OSA and the level of education,
tobacco use, comorbidity or age (Table 1). However, patients with
versus without OSA had significantly higher bodymass index (BMI),
neck- and abdominal circumference. Patients with versus without
OSA had similar eGFR.While serum albumin andC-reactive protein
(CRP) levels were similar in the two groups, the blood hemoglobin
level was higher in patients with OSA versus without OSA (Table 1).
The median transplant vintage, the median dialysis vintage and
cumulative end stage renal disease (ESRD) time were all similar in
patients with versus without OSA (Table 1). Donor characteristics
(gender, type and age) and transplant related variables (cold ischemic
time, cumulative acute rejection rate, panel reactive antibody (PRA),
delayed graft function (DGF) and human leucocyte antigen (HLA)
mismatches) were similar in patients with versus without OSA (not
shown). None of the immunosuppressive medications was signifi-
cantly associated with the presence of OSA (not shown).
Decline of graft function. In a multilevel mixed-effects model of
change of eGFR, the overall slope of eGFR versus timewas21.17 ml/
min/1.73 m2/yr (95%CI: 21.55 to 20.78) (Table 2). Figure 1 depicts
the estimated slopes of eGFR in patients with and without OSA using
different AHI cut-off level based on a two-stage model of eGFR
change. OSA was only included as a stage 2 variable, showing that
patients with OSA (eGFR versus time was 20.93 ml/min/1.73 m2/yr
(95% CI: 21.75 to 20.11) had a similar slope than patients without
OSA (eGFR versus time was 21.24 ml/min/1.73 m2/yr (95% CI:
21.67 to 20.81) (Table 2). Similar results were found using
different cut-off levels for OSA (Table 2). However, patients with
Table 1 | Patients’ characteristics at baseline
Patients with
AHI $ 15/h (n 5 25)
Patients with
AHI , 15/h (n 5 75) p value
Demographic parameters:
Male (%) 80 49 0.01
Age (mean 6 SD) (years) 54 6 12 50 6 13 0.15
Level of education (%): 24 20 0.10
Primary education or less 24 12
Skilled workers 12 40
High school or equivalent 40 28
University diploma
Anthropometric parameters:
Neck circumference (mean 6 SD) (cm) 40 6 3 37 6 4 ,0.01
Abdominal circumference (mean 6 SD) (cm) 107 6 12 95 6 15 ,0.01
BMI (mean 6 SD) (kg/m2) 29 6 5 26 6 5 ,0.01
Comorbidities:
Tobacco use (%) 20 20 1.00
Prevalence of diabetes (%) 16 20 0.66
Prevalence of hypertension (%) 100 89 0.09
Charlson Comorbidity Index (median; IQR) (point) 2; 0 2; 1 0.22
Prevalence of coronary heart disease (%) 8 8 1.00
Prevalence of congestive heart failure (%) 8 8 1.00
Prevalence of peripheral vascular disease (%) 12 12 1.00
Prevalence of cerebro-vascular disease (%) 4 1 0.41
Prevalence of atrial fibrillation (%) 8 1 0.09
Blood Pressure:
Average of systolic blood pressure (mean 6 SD) (mmHg) 147 6 21 139 6 18 0.06
Average of diastolic blood pressure (mean 6 SD) (mmHg) 85 6 13 83 6 11 0.50
Laboratory parameters:
Blood Hemoglobin (mean 6 SD) (g/L) 141 6 17 132 6 16 0.02
Serum albumin (mean 6 SD) (g/L) 40 6 4 40 6 3 0.72
Serum CRP (median; IQR) (mg/l) 3.8; 4.3 2.8; 4.6 0.43
eGFR at baseline (mean 6 SD) (ml/min./1.73 m2) 51 6 18 52 6 19 0.63
History of ESRD:
Transplant ‘‘vintage’’ (median; IQR) (months) 60; 109 67; 78 1.00
Dialysis ‘‘vintage’’ (median; IQR) (months) 25; 39 18; 28 0.24
Cumulative ESRD time (median; IQR) (months) 117; 147 96; 85 0.18
Medications:
ACE inhibitors (%) 8 24 0.08
Any type of anti-hypertensive drug (%) 92 96 0.63
Hypnotic drugs (%) 8 20 0.17
Sleep parameters:
Epworth Sleepiness scale (median; IQR) (point) 4 (5) 5 (5) 0.24
Average oxygen saturation during sleep (mean 6 SD) (%) 91.8 6 1.6 94.0 6 2.0 ,0.01
Slow wave sleep (median; IQR) (%) 9 (11) 12 (11) 0.41
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diabetes showed more rapid decline of graft function than non-
diabetic counterparts (Table 2 and Figure 1 Panel D). Additionally,
eGFR slope was similar in patients with high versus low desaturation
index (Table S2). Similar results were found in males and females
(Table S3).
In addition, neither the presence of OSA (as a categorical variable,
defined by various cut-off values) nor the AHI index (as a continuous
variable) was associated with the rapid decline of eGFR using.4 ml/
min/1.73 m2/year as a cut-off level (Table 3). Similar result was found
in a sensitivity analysis using .6 ml/min/1.73 m2/year (Table S1),
.2 ml/min/1.73 m2/year (not shown) or .8 ml/min/1.73 m2/year
as a cut-off level for rapid decline (not shown). A similar result was
found when we adjusted for baseline eGFR (not shown). Moreover,
neither the high desaturation index (as a categorical variable, defined
by cut-off 5/hour) nor the desaturation index (as a continuous vari-
able) was associated with the rapid decline of eGFR using .4 ml/
min/1.73 m2/year (Table S2). Similar results were found inmales and
females (Table S3).
All-Cause Mortality. Of the 100 participants 26 patients died and
none were lost to follow-up during amedian follow-up of 75months.
The crude all-causemortality rate (including deaths with functioning
graft and deaths after returning to dialysis) was 47.8/1000 patient-
years (95% confidence interval [CI]: 32.5–70.1). The unadjusted
Table 2 | Rate of graft function loss in patients with and without OSA – univariate analysis
eGFR changes
(ml/min/1.73 m2/year)
Confidence interval of eGFR changes
(ml/min/1.73 m2/year) p-value
All patients 21.17 (21.55)–(20.78) N/A
Patients with AHI , 5/h 21.14 (21.65)–(20.63) 0.84
Patients with AHI $ 5/h 21.21 (21.80)–(20.62)
Patients with AHI, 15/h 21.24 (21.67)–(20.81) 0.49
Patients with AHI$ 15/h 20.93 (21.75)–(20.11)
Patients with AHI, 30/h 21.24 (21.67)–(20.81) 0.38
Patients with AHI$ 30/h 20.72 (21.44)–(20.01)
Absence of diabetes 21.04 (21.46)–(20.61) 0.12
Presence of diabetes 21.88 (22.56)–(21.19)
Figure 1 | Rate of graft function loss in patients with and without OSA using 5/h (panel A), 15/h (panel B) and 30/h (panel C) as cut-off and in diabetic
patients (panel D).
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mortality rate was similar among patients with and without OSA
(crude mortality rates in the AHI $ 15/h group: 54.7/1000 patient-
years (95%CI: 26.1–114.7); AHI , 15/h group: 45.6/1000 patient-
years (95%CI: 29.1–71.5); p 5 0.68). Time to death was also similar
in patients with versus without OSA, as shown on the Kaplan-Meier
plot (Figure 2 Panel B). We found similar results using different cut-
off levels for OSA (Figure 2 Panel A and Panel C). Patients with
higher burden of comorbidity (Charlson Comorbidity Index . 2),
however, had higher unadjustedmortality rate than patients with less
comorbidities (Figure 2 Panel D).
Table 4 shows the association of all-cause mortality with OSA in
100 kidney transplant recipients. In unadjusted Cox proportional
regression analyses AHI $ 15/h was not associated with higher all-
cause mortality risk (Hazard Ratio (HR) 5 1.20; 95% Confidence
Interval (CI): 0.50–2.85). Similar results were found using different
cut-off levels for OSA or using AHI as continuous predictor variable
(Table 4). However, in our unadjusted Cox proportional regression
analyses a 1-point higher Charlson Comorbidity Index significantly
predicted all-cause mortality (HR1 point increase 5 1.28; 95% CI: 1.04–
1.58) (Table 4).
Moreover, neither the high desaturation index (as a categorical
variable, defined by cut-off 5/hour) nor the desaturation index (as a
continuous variable) was associated with the all-cause mortality
(Table S2). Similar results were found in males and females, however
there was an increased trend for higher risk of all-cause death in
females (Table S3).
Combined Outcome. Table 5 shows the association of combined
outcome (death, return to dialysis or rapid decline) with OSA in
our cohort. In unadjusted logistic regression analyses AHI $ 15/h
was not associated with higher combined outcome risk (Odds Ratio
(OR) 5 0.95; 95% CI: 0.38–2.35). Similar results were found using
different cut-off levels for OSA or using AHI as continuous predictor
variable (Table 5). However, in our unadjusted logistic regression
analyses presence of diabetes was significantly associated with
higher risk of combined outcome (OR 5 4.24; 95% CI: 1.30–13.89)
(Table 5). Moreover, neither the high desaturation index (as a
categorical variable, defined by cut-off 5/hour) nor the
desaturation index (as a continuous variable) was associated with
combined outcome (Table S2).
Discussion
In this prospective cohort study, which is one of the largest studies
using polysomnography in kidney transplant recipients, there was no
association between the presence of OSA and the rate of decline of
graft function in prevalent kidney transplant recipients. In addition,
we could not find any association between presence of OSA and all-
cause mortality in this population.
In this dataset the prevalence of OSAwas higher than published by
Mallamaci et al. recently12. One potential reason for these discordant
results may be the different methodology used. Mallamaci et al.
report the utilization of polygraphy and cardiorespiratory recording
while we used standard polysomnography with EEG. Another
explanation may be the differences in the study population. Our
sample was older, hadmore diabetics, higher BMI and had somewhat
worse mean eGFR.
The rate of decline of graft function was similar in transplant
recipients with and without OSA. This is surprising as previous data
showed strong correlation between severity of CKD and prevalence
of OSA in CKD population15, although the directionality of the asso-
ciation could not be established. However, several reports suggested
that this might be a consequence of fluid overload or nocturnal
rostral fluid overshift in these patients16–18. Further studies are
needed to assess whether the presence of OSA contributes to renal
dysfunction or progressive loss of kidney function or it is only fluid
overload associated with declining renal function that leads to the
increasing prevalence of OSA in association with worse kidney func-
tion. Another potential explanation is the fact that the renal graft is
denervated. Previous studies suggested that renal denervation, a
potential treatment of therapy resistant hypertension, had positive
Table 3 | Predictors of rapid progression (.4 ml/min/1.73 m2/year) of graft function – multivariable analysis
Model 1 Odds ratio (OR) Confidence interval of OR p-value
AHI $ 5/h (vs AHI , 5/h as reference) 1.45 0.60–3.49 0.41
Presence of diabetes (vs absence of diabetes as
reference)
2.10 0.72–6.13 0.17
Serum albumin (11 g/dl increase) 0.89 0.78–1.02 0.09
Age (110 year increase) 0.98 0.68–1.41 0.91
Model 2 Odds ratio (OR) Confidence interval of OR p-value
AHI $ 15/h (vs AHI , 15/h as reference) 0.93 0.35–2.51 0.89
Presence of diabetes (vs absence of diabetes as
reference)
2.08 0.72–6.02 0.18
Serum albumin (11 g/dl increase) 0.89 0.78–1.01 0.08
Age (110 year increase) 1.01 0.71–1.44 0.94
Model 3 Odds ratio (OR) Confidence interval of OR p-value
AHI $ 30/h (vs AHI , 30/h as reference) 0.40 0.10–1.63 0.20
Presence of diabetes (vs absence of diabetes as
reference)
2.12 0.72–6.22 0.17
Serum albumin (11 g/dl increase) 0.89 0.78–1.02 0.10
Age (110 year increase) 1.05 0.73–1.50 0.80
Model 4 Odds ratio (OR) Confidence interval of OR p-value
AHI (11/h increase) 0.99 0.96–1.02 0.58
Presence of diabetes (vs absence of diabetes as
reference)
2.06 0.71–5.96 0.18
Serum albumin (11 g/dl increase) 0.89 0.78–1.02 0.08
Age (110 year increase) 1.03 0.72–1.48 0.86
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effect on OSA19 and could potentially be utilized as an alternative
treatment for OSA20. One can speculate, that the potential negative
effect of OSA on kidney function is mediated via the relative sym-
pathetic overactivation which is transmitted to the kidney via its
sympathetic nervous supply. This could not be operational in the
transplanted kidney.
We previously showed that high risk of OSA is an independent
predictor of graft loss among female kidney transplant recipients21.
However, we used questionnaire to assess the risk of OSA in our
patients. No study was performed to assess the reliability of this
questionnaire in kidney transplant recipients, however previous
study showed that questionnaire can be unreliable in patients with
kidney disease to assess sleep disorders22. Further studies are needed
to assess the reliability of these questionnaires in kidney transplant
recipients.
There was no association between OSA and all-cause mortality or
combined outcome in our patients. OSA is an independent predictor
of mortality in the general population2,3, and overnight hypoxemia23
and OSA24 are independent predictors of cardiovascular events in
dialysis patients. Moreover, we previously showed that the presence
of OSA was associated with increased cardiovascular risk in this
population11. However, in our analysis we used the Framingham risk
score to assess cardiovascular risk11, which is not accurate to predict
cardiovascular risk in transplant population. One potential explana-
tion could be the lack of excessive daytime sleepiness (EDS) in our
patients with OSA25. As in the case of our transplant recipients, there
was very weak correlation between EDS and severity of OSA in
patients on maintenance hemodialysis26. A previous study showed
that there was no association between all-cause mortality andOSA in
elderly patients without EDS27. In addition, some studies have sug-
gested that EDS may be an important element in understanding the
clinical significance of OSA28–30, although the exact mechanism that
could link EDS and clinical outcomes is unknown. Finally, it is pos-
sible that our study lacked the sufficient power to detect a modest
difference of the outcomes of interest between patients with versus
without OSA.
Figure 2 | Presence of OSA using 5/h (panel A), 15/h (panel B) and 30/h (panel C) as cut-off and comorbidity (panel D) and all-cause mortality.
Table 4 | All-cause mortality and presence of sleep apnea – univariate analysis
Hazard ratio (HR) Confidence interval of HR p-value
AHI $ 5/h (vs AHI , 5/h as reference) 1.47 0.68–3.16 0.33
AHI $ 15/h (vs AHI , 15/h as reference) 1.20 0.50–2.85 0.68
AHI $ 30/h (vs AHI , 30/h as reference) 1.20 0.41–3.48 0.74
AHI (11/h increase) 1.01 0.98–1.03 0.62
Charlson Comorbidity Index (11 point increase) 1.28 1.04–1.58 0.02
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Limitations of this report should be noted. The prospective cohort
design precludes any causal conclusions. Determining sample size
was driven mainly by feasibility, and no formal sample size calcula-
tions had been done before the study. Post hoc power calculations
suggest that this study was powered to detect 0.25 or lower hazard
ratio of themortality between the nonOSA versusOSA groups with a
power of 80%, but the power is insufficient to detect a smaller differ-
ence. Based on this data, we can conclude that our study was under-
powered and further, larger studies are needed to confirm or reject
our results. Patients from a single center were enrolled; therefore, our
results are not to be generalized without further considerations.
Finally, a substantial proportion of transplant recipients refused to
participate (Figure S1). Importantly, we did not find any difference
between participants versus nonparticipants; therefore, it is unlikely
that refusal introduced a systematic bias that would distort our con-
clusions significantly. Refusal rate was similar in other studies that
used polysomnography in end stage renal disease population10,31. We
also acknowledge that there is a potentially ‘‘unavoidable’’ selection
bias that affects all studies of sleep disorders that are based on poly-
somnography, such as ours: only motivated or symptomatic patients
accept the stress of polysomnography, whereas ‘‘good sleepers’’ may
opt to avoid this test. We cannot exclude the presence of this bias in
our study.
Conclusion
This is the first report to present data from a large number of trans-
plant recipients regarding the association between OSA and long-
term clinical outcomes, such as decline of graft function and all-cause
mortality in kidney transplant recipients. The rate of progression of
graft function and all-cause mortality were similar in transplant
recipients with and without OSA. Further, larger studies are needed
to confirm or reject our results before we can make any recom-
mendation for screening and treatment of OSA in kidney transplant
recipients.
Methods
Sample of patients and data collection. For this study (‘‘SLeep disorders Evaluation
in Patients after kidney Transplantation (SLEPT) Study’’) potentially eligible patients
were selected from all prevalent adult transplant recipients (‘‘total clinic population;
n 5 1214) who were regularly followed at a single outpatient transplant center on
December 31, 2006. After applying exclusion criteria (previous diagnosis of OSA,
recent start (less than 3months) on dialysis or transplant, active and acute respiratory
disorder, acute infection, hospitalization within 1 month, surgery within 3 months)
1198 patients remained (‘‘base population’’; n 5 1198). From this ‘‘base population’’
we randomly selected and approached 150 patients (‘‘Tx study sample’’) using the
simple random sampling strategy offered by SPSS 15.0 (Figure S1). From these 150
patients 100 patients agreed to participate. They underwent one overnight
polysomnography and were followed for a median of 6 years. Detailed history
including age, gender, level of education, tobacco use and etiology and history of CKD
were collected at enrolment.
Polysomnography. Standard, attended overnight polysomnography was performed
in our sleep laboratory (SOMNOscreenTM PSG Tele, SOMNOmedics GmBH,
Germany, CE0494). Recordings were manually scored by two somnologists. Sleep
stages were determined in 30 s epochs according to Rechtschaffen and Kales32. Apnea
was defined as the absence of airflow for more than 10 s; hypopnea was defined as a
clearly discernible reduction in airflow for more than 10 s associated with an arousal
and/or reduction in oxygen saturation.3%33. The AHI was defined as the number of
apneas and hypopneas per hour of sleep. Similarly to previous publications34,35 the
term ‘OSA’ refers tomoderate or severe apnea (AHI$ 15) in this paper, unless stated
otherwise. Desaturation index was defined as the number of desaturations per hour of
sleep.We used 5/hour for definition of high versus low number of desaturation index.
Laboratory data. Laboratory, demographic, anthropometric, medication data and
single pool (sp) Kt/V were extracted from the medical records. Estimated glomerular
filtration rate (eGFR) was calculated using the abbreviated Modification of Diet in
Renal Disease (MDRD) study formula36.
Comorbidity. Comorbidity was assessed by the modified Charlson Comorbidity
Index (CCI)37,38 completed by the transplant physician responsible for the given
patient. We also collected data about coronary disease and hypertension from the
medical records.
Transplantation and donor related data; immunosuppressive therapy.
Transplantation related information collected included current medications,
transplant and dialysis ‘‘vintage’’ (i.e. time elapsed since transplantation or since the
initiation of dialysis treatment), time spent on dialysis prior to transplantation, type of
transplantation (deceased donor or living donor), history of cumulative acute
rejection, HLA mismatch, titer of pre-transplant panel reactive antibodies (PRA),
cold ischemic time (CIT), age and gender of donor and history of delayed graft
function. Time elapsed since the initiation of the first treatment for ESRD (cumulative
ESRD time) was also calculated. Standard maintenance immunosuppressive therapy
generally consisted of prednisolone, either CsA or tacrolimus, combined with MMF
or azathioprine, everolimus or sirolimus.
Follow-up. Patients were followed for an average 75 months (median, [interquartile
range - IQR]: 75.2 [69.9–77.0] months). The primary outcome variable was
deterioration of graft function. We collected each patient’s eGFR in every 6 months
for the entire follow-up period. If a patient was started on dialysis or re-transplanted
or eGFRwas less than 15 ml/min/1.73 m2 the last value was the last available eGFR or
the last value below 15 ml/min/1.73 m2 and no further data was collected. The ‘‘rapid
decline of graft function’’ status was defined if the deterioration of eGFR was higher
than 4 ml/min/1.73 m2/year. The secondary outcome variable was all-cause
mortality, which included all deaths with a functioning graft and deaths occurring
after the graft failure (i.e. after initiation of dialysis). Deaths and re-initiations of
maintenance dialysis were ascertained from the hospital database. Deaths were
validated by cross-referencing with data from the Hungarian Central Office of
Administrative and Electronic Public Service, which is the government agency
maintaining official vital status records. In addition, we also performed a sensitivity
analysis using combined outcome, defined as death of any cause or return to dialysis
or rapid decline of graft function (deterioration of eGFR was higher than 4 ml/min/
1.73 m2/year) of graft function. None of our patients were treated for OSA at baseline
or during the follow-up period, however CPAP treatment was offered all of them.
Ethical approval. The study was approved by the Ethics Committee of the
Semmelweis University (4/2007). Before enrolment, patients received detailed verbal
and written information about the aims and protocol of the study and signed an
informed consent. All experiments were performed in accordance with relevant
guidelines and regulations.
Statistical Analysis. Statistical analyses were carried out using the STATA 12.1
software. Results are presented as percentage, mean (6standard deviation, SD) or
medians (interquartile range, IQR). Continuous variables were compared using
Student’s t-test or the Mann-Whitney U test and categorical variables were analyzed
with chi-square test. In all statistics, two-sided test were used and the results were
considered statistically significant if p was less than 0.05.
For multivariate analysis, logistic- and Cox regressions were applied. Independent
variables were included in the multivariate models based on theoretical considera-
tions. Variance influence factors (VIF) were used to indicate collinearity between
independent variables. The association between baseline AHI level and all-cause
mortality was assessed using Cox proportional regression analysis and Kaplan-Meier
plots with log rank test. Proportional hazards assumptions were tested using scaled
Schoenfeld residuals.
The association between the presence of OSA (using different AHI cut-off levels)
and the slopes of eGFR versus time were examined in generalized linear mixed-effects
models allowing for a random intercept and slope using the ‘‘XTMIXED’’ command
in STATA. The change in eGFR from baseline until death, start of dialysis, or re-
Table 5 | Combined outcome (death or graft loss or rapid progression (.4 ml/min/1.73 m2/year) of graft function) and presence of sleep
apnea – univariate analysis
Odds ratio (OR) Confidence interval of OR p-value
AHI $ 5/h (vs AHI , 5/h as reference) 1.44 0.65–3.19 0.37
AHI $ 15/h (vs AHI , 15/h as reference) 0.95 0.38–2.35 0.91
AHI $ 30/h (vs AHI , 30/h as reference) 0.62 0.20–1.95 0.42
AHI (11/h increase) 1.00 0.97–1.03 0.68
Presence of diabetes (vs absence of diabetes) 4.24 1.30–13.89 0.02
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transplantation (whichever occurred first) was studied in all transplant recipients
who had at least three serum creatinine measurements (n 5 100; median number of
measurments 5 8, range: 3 to 14) by using a two-stage model formulation. In such a
model, the level 1 change describes intra-individual changes in eGFR, and the level 2
model describes how the change coefficients differ across participants. The covariate
of interest (AHI as independent variable) is thus included in the level 2 models to
explain interindividual differences in intra-individual change (slope).
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